GLP-1 and Breastfeeding: Safety Data and Recommendations

Written by Adam Maggio | Medically reviewed by Dr. James Whitfield, DO, FACOI

GLP-1 receptor agonists are generally not recommended during breastfeeding due to insufficient human safety data and potential for infant exposure; alternative weight management strategies are preferred for lactating mothers.

# GLP-1 and Breastfeeding: Safety Data and Recommendations

Glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide and liraglutide, are increasingly used for weight management and type 2 diabetes. For postpartum women, particularly those struggling with gestational diabetes or postpartum weight retention, the question of using these medications while breastfeeding is highly relevant. However, current data on the safety of GLP-1RAs during lactation are limited, necessitating a cautious approach.

Understanding the Lack of Data

Limited Human Studies: There are no adequate and well-controlled studies in lactating women regarding the presence of GLP-1RAs in human milk, their effects on the breastfed infant, or their effects on milk production. Most clinical trials for these medications exclude breastfeeding mothers, leaving a significant gap in our understanding of their safety during lactation.

Animal Studies: Animal studies have shown that GLP-1RAs are excreted into the milk of lactating rats. While the relevance of these animal findings to humans is uncertain, they suggest a potential for infant exposure. The concentration of the drug in milk and the extent of absorption by the infant are unknown in humans.

Molecular Characteristics: GLP-1RAs are large peptide molecules. Generally, larger molecules are less likely to pass into breast milk in significant amounts. However, the specific characteristics of each GLP-1RA (e.g., molecular weight, protein binding, half-life) can influence its transfer into milk and potential oral bioavailability in the infant. For instance, semaglutide has a long half-life (approximately one week), meaning it remains in the mother"s system for an extended period.

Potential Concerns for the Breastfed Infant

Given the lack of data, potential concerns for a breastfed infant exposed to GLP-1RAs include:

Gastrointestinal Effects: As GLP-1RAs act on the gastrointestinal system, there is a theoretical concern for effects such as nausea, vomiting, diarrhea, or changes in appetite in the infant.

Hypoglycemia: While less likely due to the glucose-dependent mechanism of action, there is a theoretical risk of hypoglycemia in the infant, especially if the infant is particularly sensitive or if milk concentrations are high.

Developmental Effects: The long-term developmental effects of GLP-1RA exposure in infants are unknown.

Impact on Milk Supply: It is also unknown whether GLP-1RAs could affect milk production in the mother, given their metabolic effects.

Clinical Recommendations and Considerations

Based on the current limited evidence, the general recommendation from manufacturers and many healthcare professional organizations is to avoid using GLP-1RAs during breastfeeding.

Key Recommendations:

Prioritize Infant Safety: In situations where the risks are unknown, the safest approach is to avoid exposure to the infant.

Discuss with Healthcare Provider: Lactating mothers considering GLP-1RAs should have a thorough discussion with their healthcare provider to weigh the potential benefits to the mother against the unknown risks to the infant.

Alternative Weight Management Strategies: For postpartum weight management, lifestyle interventions (diet and exercise) are generally recommended as first-line approaches during breastfeeding. If pharmacotherapy is deemed necessary, agents with more established safety profiles during lactation should be considered.

Monitor the Infant: If a mother chooses to continue or initiate a GLP-1RA while breastfeeding after careful consideration and discussion with her doctor, close monitoring of the infant for any adverse effects (e.g., feeding changes, gastrointestinal symptoms, growth) is crucial.

Pump and Dump (Not Recommended): Due to the long half-life of some GLP-1RAs (like semaglutide), "pumping and dumping" milk is generally not an effective strategy to avoid infant exposure.

Conclusion

The use of GLP-1 receptor agonists during breastfeeding is currently not recommended due to insufficient human safety data and theoretical concerns regarding infant exposure. While these medications offer significant benefits for maternal health, the unknown risks to the breastfed infant necessitate a cautious approach. Lactating mothers should prioritize infant safety, discuss all options with their healthcare provider, and explore alternative weight management strategies that have established safety profiles during breastfeeding. As more research emerges, these recommendations may evolve, but until then, prudence is advised.